Galderma marks the 25th anniversary of RESTYLANE. Since launching in Europe in 1996 and becoming the first hyaluronic acid filler approved by the US Food and Drug Administration (FDA) in 2003, RESTYLANE has celebrated many milestones across the globe.

Now, in its 25th year, the RESTYLANE portfolio continues to grow and expand. Since RESTYLANE’s US FDA approval in 2003, there have been 13 dermal filler product approvals and launches. The RESTYLANE portfolio offers a diverse range of fillers by using two complementary gel technologies, NASHA and XpresHAn (globally referred to as the OBT technology (Optimal Balance Technology)), to provide personalized, natural-looking results that deliver high patient satisfaction, according to a news release from the company.

In February, the FDA approved RESTYLANE DEFYNE for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. In June, RESTYLANE added a new product to the portfolio, RESTYLANE CONTOUR, for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21, becoming the first and only product in the US to use proprietary XpresHAn Technology for the cheeks. These approvals mark major successes for the industry-standard filler.

“The depth of experience from RESTYLANE over the last 25 years has enabled us to build upon our expertise to innovate and develop new formulations and treatments. With over 30 ongoing pipeline projects in aesthetics alone, we will continue to enhance our diverse and broad portfolio of sophisticated brands to advance dermatology for every skin story.”

— Flemming Ørnskov, MD, MPH, Chief Executive Officer at Galderma

About Galderma’s Restylane Product Portfolio

These products help smooth facial wrinkles and folds, such as smile lines (Restylane L, Restylane Refyne, Restylane Defyne and Restylane Lyft with Lidocaine), augment and correct mild to moderate chin retrusion (Restylane Defyne), create fuller and more accentuated lips (Restylane Silk, Restylane-L and Restylane Kysse), add lift and volume to the cheeks and back of the hands (Restylane Lyft with Lidocaine), and augment cheeks and correct midface contour deficiencies (Restylane Contour).

[Source(s): Galderma, PR Newswire]

Related Content:
Latest FDA Approval Helps Galderma Expand a Growing Restylane Product Portfolio
FDA Approves Restylane Contour
Galderma Receives FDA Approval for Restylane Kysse Lip Augmentation Filler